Shares of Immunex Corp. rose $5.13 to $56.63 on Wednesdayafter the Seattle company (NASDAQ:IMNX) said it wouldannounce today a marketing agreement for certain of itsoncology products.

"The marketing alliance relates to the exchange of rights forcertain oncology products," said spokesman Jason Rubin. Hesaid the agreement does not include Leukine granulocytemacrophage colony stimulating factor, which the companymarkets to restore white blood cells in bone marrow transplantpatients following chemotherapy.

Rubin told BioWorld that the agreement covers one of the threeother products in Immunex's oncology pipeline: PIXY321,interleukin-1 alpha and IL-1 receptor.

PIXY321 combines in a single molecule analogs of twocytokines, GM-CSF and interleukin-3. The drug is in Phase Itrials to restore platelets and white blood cells in patients withsarcoma, gastrointestinal cancers and refractory solid tumors.

IL-1 alpha is in Phase II trials to restore white blood cells andtreat melanoma, and in Phase I/II trials to restore platelets.IL-1 receptor is in Phase I/II trials for rheumatoid arthritisand allergy.

-- Karen Bernstein BioWorld Staff

(c) 1997 American Health Consultants. All rights reserved.